- Home
- SGA vs CNTX Comparison
SGA vs CNTX Comparison
Compare SGA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | CNTX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 47.7M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGA | CNTX |
|---|---|---|
| Price | $8.90 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 13.9K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $8.24 | $0.40 |
| 52 Week High | $13.05 | $3.62 |
Technical Indicators
Market Signals| Indicator | SGA | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 32.72 |
| Support Level | $8.26 | N/A |
| Resistance Level | $9.42 | $0.55 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 1.52 | 17.07 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.